|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/18 | |
| C12N 5/16 | |||
| A61K 39/395 | |||
| A61P 35/00 |
| (11) | Number of the document | 2471814 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10811290.5 |
| Date of filing the European patent application | 2010-08-27 | |
| (97) | Date of publication of the European application | 2012-07-04 |
| (45) | Date of publication and mention of the grant of the patent | 2018-01-03 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/CN2010/076420 |
| Date | 2010-08-27 |
| (87) | Number | WO 2011/023130 |
| Date | 2011-03-03 |
| (30) | Number | Date | Country code |
| 200910171550 | 2009-08-28 | CN |
| (72) |
LI, Pierre, US
KE, Yaohuang, US
ZHANG, Yongke, US
ZHU, Weimin, US
YU, Guoliang, US
MA, Fanxin, CN
FAN, Xin, CN
|
| (73) |
Jiangsu Simcere Pharmaceutical Co., Ltd,
No.699-18 Xuanwu Avenue Xuanwu District, Nanjing, Jiangsu 210042,
CN
Apexigen, Inc., 863 Mitten Road, Suite 103, Burlingame, California 94010, US |
| (54) | ANTI-VEGF MONOCLONAL ANTIBODY AND PHARMACEUTICAL COMPOSITION COMPRISING SAID ANTIBODY |
| ANTI-VEGF MONOCLONAL ANTIBODY AND PHARMACEUTICAL COMPOSITION COMPRISING SAID ANTIBODY |